Immunohistochemical Expression of Proinflammatory Enzyme COX-2 and P53 in Ulcerative Colitis and Its Associated Dysplasia and Colorectal Carcinoma

Overview

Journal J Microsc Ultrastruct

Date 2018 Jul 20

PMID 30023227

Citations 3

Authors

Nehal Mohamed Elmashad

Dina H Ziada

Eiman A Hasby

Abd El Motaleb Mohamed

Affiliations

Soon will be listed here.

Abstract

Background/aim: Ulcerative colitis (UC) patients are at increased risk for colorectal carcinoma (CRC). It is suggested that cyclooxygenase-2 (COX-2) plays a role in sporadic CRC. The gene is a tumor-suppressor gene and the most frequent site of genetic alteration found in human cancer. The aim of this study was to analyze the immunoexpression of proinflammatory enzyme COX-2 and p53 in UC, UC-associated dysplasia, and CRC, in comparison with each other and with different clinical and histopathological parameters, to clarify if they have a possible role in the pathogenesis of CRC in UC patients.

Materials And Methods: In this cross-sectional study, 98 patients were divided into three groups: 39 patients with UC without dysplasia, 32 patients with UC with dysplasia, and 27 patients with colorectal cancer on top of UC, in addition to 10 healthy controls. All patients underwent colonoscopy, and multiple biopsies were taken for histopathological and COX-2 and p53 immunohistochemical studies.

Results: There was significant difference in the expression of COX-2 and p53 in UC-related dysplasia either without or with CRC, compared with their expression in the UC group without dysplasia.

Conclusion: Adding immunohistochemical analysis of COX-2 enzyme and p53 gene to routine histological assessment may improve the accuracy of early detection of dysplasia and colorectal cancer. COX-2 and p53 can be promising chemotherapeutic/chemopreventive targets in UC patients.

Citing Articles

Molecular Mechanisms and Clinical Aspects of Colitis-Associated Cancer in Ulcerative Colitis.

Yamamoto-Furusho J, Gutierrez-Herrera F Cells. 2025; 14(3).

PMID: 39936954 PMC: 11817687. DOI: 10.3390/cells14030162.

Role of glycolysis in inflammatory bowel disease and its associated colorectal cancer.

Xia Y, Zhang L, Ocansey D, Tu Q, Mao F, Sheng X Front Endocrinol (Lausanne). 2023; 14:1242991.

PMID: 37881499 PMC: 10595037. DOI: 10.3389/fendo.2023.1242991.

Mechanism of Jianpi Qingchang Huashi Recipe in treating ulcerative colitis: A study based on network pharmacology and molecular docking.

Zheng L, Wen X, Dai Y World J Clin Cases. 2021; 9(26):7653-7670.

PMID: 34621817 PMC: 8462257. DOI: 10.12998/wjcc.v9.i26.7653.

Angiogenin regulates PKD activation and COX-2 expression induced by TNF-α and bradykinin in the colonic myofibroblast.

Plummer R, Hu G, Liu T, Yoo J Biochem Biophys Res Commun. 2020; 525(4):870-876.

PMID: 32171525 PMC: 7233487. DOI: 10.1016/j.bbrc.2020.02.169.

References

Eaden J, Abrams K, Mayberry J . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-35. PMC: 1728259. DOI: 10.1136/gut.48.4.526. View

Ogino S, Brahmandam M, Kawasaki T, Kirkner G, Loda M, Fuchs C . Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia. 2006; 8(6):458-64. PMC: 1601473. DOI: 10.1593/neo.06247. View

Kornbluth A, Sachar D . Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105(3):501-23. DOI: 10.1038/ajg.2009.727. View

Thia K, Loftus Jr E, Pardi D, Kane S, Faubion W, Tremaine W . Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2010; 17(6):1257-64. DOI: 10.1002/ibd.21480. View

Yu Y, Fan J, Hui Y, Rouzer C, Marnett L, Klein-Szanto A . Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. J Biol Chem. 2006; 282(2):1498-506. DOI: 10.1074/jbc.M609930200. View

Xie J, Itzkowitz S . Cancer in inflammatory bowel disease. World J Gastroenterol. 2008; 14(3):378-89. PMC: 2679126. DOI: 10.3748/wjg.14.378. View

Tanaka T . Development of an inflammation-associated colorectal cancer model and its application for research on carcinogenesis and chemoprevention. Int J Inflam. 2012; 2012:658786. PMC: 3299397. DOI: 10.1155/2012/658786. View

Kulaylat M, Dayton M . Ulcerative colitis and cancer. J Surg Oncol. 2010; 101(8):706-12. DOI: 10.1002/jso.21505. View

Giovannucci E, Egan K, Hunter D, Stampfer M, Colditz G, Willett W . Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995; 333(10):609-14. DOI: 10.1056/NEJM199509073331001. View

10.

Schernhammer E, Ogino S, Fuchs C . Folate and vitamin B6 intake and risk of colon cancer in relation to p53 expression. Gastroenterology. 2008; 135(3):770-80. PMC: 2634965. DOI: 10.1053/j.gastro.2008.06.033. View

11.

Risques R, Lai L, Himmetoglu C, Ebaee A, Li L, Feng Z . Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res. 2011; 71(5):1669-79. PMC: 3077943. DOI: 10.1158/0008-5472.CAN-10-1966. View

12.

Stapley S, Peters T, Sharp D, Hamilton W . The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records. Br J Cancer. 2006; 95(10):1321-5. PMC: 2360591. DOI: 10.1038/sj.bjc.6603439. View

13.

Gonzalez-Hermoso F, Perez-Palma J, Marchena-Gomez J, Lorenzo-Rocha N, Medina-Arana V . Can early diagnosis of symptomatic colorectal cancer improve the prognosis?. World J Surg. 2004; 28(7):716-20. DOI: 10.1007/s00268-004-7232-8. View

14.

Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R . Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract. 2008; 204(7):511-24. DOI: 10.1016/j.prp.2008.04.011. View

15.

Mattar M, Lough D, Pishvaian M, Charabaty A . Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res. 2011; 4(2):53-61. PMC: 3109885. View

16.

Fratila O, Ilias T . COX-2 and Ki-67 immunohistochemical markers in the assessment of long-standing ulcerative colitis associated dysplasia. Rom J Morphol Embryol. 2013; 54(1):143-9. View

17.

Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G . Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2012; 7(1):1-33. DOI: 10.1016/j.crohns.2012.09.005. View

18.

Curtin K, Slattery M, Holubkov R, Edwards S, Holden J, Samowitz W . p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry. Appl Immunohistochem Mol Morphol. 2004; 12(4):380-6. DOI: 10.1097/00129039-200412000-00017. View

19.

Svec J, Musilkova J, Bryndova J, Jirasek T, Mandys V, Kment M . Enhanced expression of proproliferative and antiapoptotic genes in ulcerative colitis-associated neoplasia. Inflamm Bowel Dis. 2009; 16(7):1127-37. DOI: 10.1002/ibd.21178. View

20.

Paiotti A, Artigiani Neto R, Forones N, Oshima C, Miszputen S, Franco M . Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis. Braz J Med Biol Res. 2007; 40(7):911-8. DOI: 10.1590/s0100-879x2006005000128. View